ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2026
Putative glymphatic function and free water in schizophrenia: A 7T DTI study across psychosis stages.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The olfactory-glymphatic syndrome: linking smell dysfunction, cognitive impairment and sleep disturbances in neuropathological disorders.Frontiers in neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Schizophrenia is characterized by impaired brain health, including gray matter reductions and cognitive dysfunction, with vascular and glymphatic dysfunction emerging as key contributors. The glymphatic system, which clears metabolic waste via perivascular pathways, is measurable using Diffusion Tensor Imaging-Along the Perivascular Space (DTI-ALPS) and its dysfunction is suspected to increase extracellular free water (FW). Prior studies reported potential glymphatic impairment in schizophrenia, but its relationship to the stage of illness and impact on interstitial fluid dynamics remains unclear. This study employed ultra-high field (7-Tesla) DTI to quantify DTI-ALPS and FW in white and gray matter in 125 subjects, including clinical high-risk (CHR), untreated first-episode psychosis (FEP), established schizophrenia (>3 years), and healthy controls (HC). We investigated: (1) the presence of DTI-ALPS alterations in CHR and its relative magnitude across disease stages; (2) its association with symptom severity; (3) its correlation with FW; and (4) its relationship to likely origins of neuroanatomical progression in schizophrenia from the hippocampal region. Compared with HC, the established, FEP and CHR all showed lower DTI-ALPS (p < 0.01 for all, Hedge's g = 0.73-1.13) and higher white matter FW (p < 0.05 for all, g = 0.59-1.57). Lower DTI-ALPS was correlated with higher FW, longer duration of untreated psychosis, and was selectively pronounced in the FEP subgroup, whose structural changes may originate from the hippocampal region. Our findings suggested that the putative glymphatic dysfunction indexed by DTI-ALPS predates antipsychotics, drives interstitial fluid accumulation, and contributes to schizophrenia's structural and clinical progression, offering mechanistic insights into its pathophysiology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.